129 related articles for article (PubMed ID: 1699658)
1. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients.
Avramis VI; Champagne J; Sato J; Krailo M; Ettinger LJ; Poplack DG; Finkelstein J; Reaman G; Hammond GD; Holcenberg JS
Cancer Res; 1990 Nov; 50(22):7226-31. PubMed ID: 1699658
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity.
Leiby JM; Snider KM; Kraut EH; Metz EN; Malspeis L; Grever MR
Cancer Res; 1987 May; 47(10):2719-22. PubMed ID: 2436757
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trials with fludarabine phosphate.
Von Hoff DD
Semin Oncol; 1990 Oct; 17(5 Suppl 8):33-8. PubMed ID: 1699281
[TBL] [Abstract][Full Text] [Related]
5. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
Malspeis L; Grever MR; Staubus AE; Young D
Semin Oncol; 1990 Oct; 17(5 Suppl 8):18-32. PubMed ID: 1699279
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive phase I and II clinical investigation of fludarabine phosphate.
Grever M; Leiby J; Kraut E; Metz E; Neidhart J; Balcerzak S; Malspeis L
Semin Oncol; 1990 Oct; 17(5 Suppl 8):39-48. PubMed ID: 1699282
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule.
Leiby JM; Grever MR; Staubus AE; Neidhart JA; Malspeis L
J Natl Cancer Inst; 1988 May; 80(6):447-9. PubMed ID: 2452888
[TBL] [Abstract][Full Text] [Related]
10. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study.
Spriggs DR; Stopa E; Mayer RJ; Schoene W; Kufe DW
Cancer Res; 1986 Nov; 46(11):5953-8. PubMed ID: 2428488
[TBL] [Abstract][Full Text] [Related]
12. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.
Warrell RP; Berman E
J Clin Oncol; 1986 Jan; 4(1):74-9. PubMed ID: 2416889
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
14. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
15. [Phase II clinical study of SH L 573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia].
Miyawaki S; Imamura M; Kobayashi S; Ohnishi K; Hodohara K; Mizoguchi H; Tomonaga M; Tango T; Ohno R
Rinsho Ketsueki; 1999 Dec; 40(12):1236-44. PubMed ID: 10658476
[TBL] [Abstract][Full Text] [Related]
16. [Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma].
Arima N; Mizoguchi H; Shirakawa S; Tomonaga M; Takatsuki K; Ohno R
Gan To Kagaku Ryoho; 1999 Apr; 26(5):619-29. PubMed ID: 10234292
[TBL] [Abstract][Full Text] [Related]
17. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
Liliemark JO; Plunkett W; Dixon DO
Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.
Hutton JJ; Von Hoff DD; Kuhn J; Phillips J; Hersh M; Clark G
Cancer Res; 1984 Sep; 44(9):4183-6. PubMed ID: 6204752
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics and proposed mechanism of therapeutic action and host toxicity of 9-beta-D-arabinofuranosyl-2-fluoroadenine monophosphate (F-araAMP) in P388 murine leukemia-bearing mice.
Avramis VI
Cancer Invest; 1989; 7(2):129-37. PubMed ID: 2477118
[TBL] [Abstract][Full Text] [Related]
20. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Seymour JF; Huang P; Plunkett W; Gandhi V
Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]